Switching adult patients with spasticity from onabotulinumtoxinA to abobotulinumtoxinA: a real-world data analysis across three US-based treatment centers
Journal of Comparative Effectiveness Research · 2026-05 · 15 (5)
DOI: 10.57264/cer-2025-0181 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Comparative Effectiveness Research, 2026-05. Verfasst von Nate Way und 6 weiteren Autor:innen. Beteiligte Einrichtung: Real World Evidence, Cerner Enviza, an Oracle Company, Malvern, PA 19301, USA. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Muscle Spasticity, Neuromuscular Agents, Drug Substitution. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
To assess patient characteristics, treatment patterns, botulinum toxin type-A (BoNT-A) costs and describe safety in adults with spasticity who switched from onabotulinumtoxinA to abobotulinumtoxinA. Materials & methods: Chart data from three US-based treatment centers was collected in patients aged ≥18 years with upper limb (ULS), lower limb (LLS) or ULS and LLS (ULS + LLS) spasticity. Eligible patients had ≥2 onabotulinumtoxinA treatment cycles before switching to abobotulinumtoxinA; they were followed for three additional abobotulinumtoxinA treatment cycles. A post hoc analysis of estimated drug costs was conducted.
Results
Eighty-eight patients (mean age 44.9 years; 62.5% male) switched from onabotulinumtoxinA to abobotulinumtoxinA; in 84 (95.5%), the switch was due to ‘medical need/effectiveness not achieved.’ Most common spasticity etiologies were cerebral palsy (43.2%) and stroke (25.0%). Fifty-one patients (58.0%) had bilateral spasticity with a mean ± SD of 5.1 ± 2.2 muscles injected at each visit over the 5-injection-cycle treatment period. No adverse events were reported following switching. Mean estimated cost per visit was $2731 with onabotulinumtoxinA and $1452 with abobotulinumtoxinA.
Conclusion
In this real-world study, patients with ULS, LLS or ULS + LLS who were switched from onabotulinumtoxinA to abobotulinumtoxinA continued for ≥3 treatment cycles without any reported adverse events. Switching resulted in lower estimated BoNT-A costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Real World Evidence, Cerner Enviza, an Oracle Company, Malvern, PA 19301, USA.
- Beaumont Health, Royal Oak, MI 48073, USA.
- The Center for Tone Management of the Main Line, Paoli, PA 19301, USA.
- OrthoNeuro, New Albany, OH 43054, USA.
- Ipsen, Cambridge, MA 02142, USA.
Zitieren
APA
Way, N., Dabrowski, E., Paulin, M., Taylor, M., Madden, J., Mann, A., & Bouchard, J. (2026). Switching adult patients with spasticity from onabotulinumtoxinA to abobotulinumtoxinA: a real-world data analysis across three US-based treatment centers. Journal of Comparative Effectiveness Research, 15(5). https://doi.org/10.57264/cer-2025-0181
Vancouver
Way N, Dabrowski E, Paulin M, Taylor M, Madden J, Mann A, et al. Switching adult patients with spasticity from onabotulinumtoxinA to abobotulinumtoxinA: a real-world data analysis across three US-based treatment centers. Journal of Comparative Effectiveness Research. 2026;15(5). doi:10.57264/cer-2025-0181
BibTeX
@article{Way2026,
author = {Way, Nate and Dabrowski, Edward and Paulin, Mitchell and Taylor, Martin and Madden, John and Mann, Amandeep and Bouchard, Jonathan},
title = {Switching adult patients with spasticity from onabotulinumtoxinA to abobotulinumtoxinA: a real-world data analysis across three US-based treatment centers},
journal = {Journal of Comparative Effectiveness Research},
year = {2026},
volume = {15},
number = {5},
doi = {10.57264/cer-2025-0181}
}
EUVIMED